However, the clinical benefit of immunotherapy based on CTLA-4-specific antibodies in B cell lymphoma diseases, even in combination with other monoclonal antibodies, is low.45 The gene discussed is CTLA4; the disease is B-cell non-Hodgkin lymphoma.